MANIFEST-2, a global, phase 3, randomized, double-blind, active-control study of CPI-0610 and Ruxolitinib vs. placebo and Ruxolitinib in JAKi-treatment-naive Myelofibrosis (MF) patients
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2021）
关键词
MPN, myelofibrosis, CPI-0610, BETi, JAKi, MANIFEST
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要